FDA Approves Voceryq for Recurrent Respiratory Papillomatosis
The FDA granted accelerated approval to Voceryq, the first plasmid DNA-based immunotherapy approved in the US for adult patients with recurrent respiratory papillomatosis (RRP).
Tag: RRP recurrent respiratory papillomatosis
FDA Approves Voceryq for Recurrent Respiratory Papillomatosis
The FDA granted accelerated approval to Voceryq, the first plasmid DNA-based immunotherapy approved in the US for adult patients with recurrent respiratory papillomatosis (RRP).
Read More
Long-Term Data for Recurrent Respiratory Papillomatosis Therapy
Updated clinical data demonstrates that Papzimeos for adults with Recurrent Respiratory Papillomatosis (RRP) can maintain complete responses for more than four years.
Read More